Based on the key indicators related to Haemonetics' liquidity, profitability, solvency, and operating efficiency, Haemonetics is performing exceptionally good at this time. It has a great probability to report excellent financial results in April. At present, Haemonetics' Short and Long Term Debt Total is projected to increase significantly based on the last few years of reporting. The current year's Other Current Liabilities is expected to grow to about 224.1 M, whereas Retained Earnings are forecasted to decline to about 281.9 M. Key indicators impacting Haemonetics' financial strength include:
The financial analysis of Haemonetics is a critical element in measuring its lifeblood. Investors should not minimize Haemonetics' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Cash And Equivalents
214.13 Million
Haemonetics
Select Account or Indicator
Price To Sales Ratio
Ptb Ratio
Days Sales Outstanding
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Stock Based Compensation To Revenue
Capex To Depreciation
Pb Ratio
Ev To Sales
Free Cash Flow Per Share
Roic
Inventory Turnover
Net Income Per Share
Days Of Inventory On Hand
Payables Turnover
Research And Ddevelopement To Revenue
Capex To Revenue
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Intangibles To Total Assets
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Receivables Turnover
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Revenue Per Share
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Pretax Profit Margin
Ebt Per Ebit
Operating Profit Margin
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Ebit Per Revenue
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Net Income Per E B T
Cash Ratio
Cash Conversion Cycle
Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding
Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios
Price To Book Ratio
Fixed Asset Turnover
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Price Sales Ratio
Return On Assets
Asset Turnover
Net Profit Margin
Gross Profit Margin
Price Fair Value
Return On Equity
Sale Purchase Of Stock
Change To Inventory
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Other Cashflows From Financing Activities
Depreciation
Other Non Cash Items
Dividends Paid
Capital Expenditures
Total Cash From Operating Activities
Net Income
Total Cash From Financing Activities
End Period Cash Flow
Change To Account Receivables
Stock Based Compensation
Other Cashflows From Investing Activities
Total Cashflows From Investing Activities
Change To Netincome
Change To Liabilities
Change Receivables
Net Borrowings
Exchange Rate Changes
Cash And Cash Equivalents Changes
Cash Flows Other Operating
Investments
Change To Operating Activities
Common Stock Shares Outstanding
Total Assets
Short Long Term Debt Total
Other Current Liab
Total Current Liabilities
Total Stockholder Equity
Property Plant And Equipment Net
Net Debt
Retained Earnings
Accounts Payable
Cash
Non Current Assets Total
Non Currrent Assets Other
Cash And Short Term Investments
Net Receivables
Liabilities And Stockholders Equity
Non Current Liabilities Total
Inventory
Other Current Assets
Other Stockholder Equity
Total Liab
Property Plant And Equipment Gross
Total Current Assets
Accumulated Other Comprehensive Income
Short Term Debt
Intangible Assets
Common Stock Total Equity
Short Term Investments
Common Stock
Other Liab
Other Assets
Long Term Debt
Good Will
Property Plant Equipment
Current Deferred Revenue
Net Tangible Assets
Retained Earnings Total Equity
Long Term Debt Total
Capital Surpluse
Deferred Long Term Liab
Non Current Liabilities Other
Accumulated Depreciation
Deferred Long Term Asset Charges
Short Long Term Debt
Cash And Equivalents
Net Invested Capital
Net Working Capital
Capital Stock
Capital Lease Obligations
Interest Expense
Total Revenue
Gross Profit
Operating Income
Ebit
Ebitda
Depreciation And Amortization
Other Operating Expenses
Cost Of Revenue
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Income Tax Expense
Research Development
Selling General Administrative
Net Income Applicable To Common Shares
Extraordinary Items
Net Income From Continuing Ops
Non Operating Income Net Other
Selling And Marketing Expenses
Non Recurring
Tax Provision
Interest Income
Net Interest Income
Reconciled Depreciation
Probability Of Bankruptcy
Understanding current and past Haemonetics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Haemonetics' financial statements are interrelated, with each one affecting the others. For example, an increase in Haemonetics' assets may result in an increase in income on the income statement.
Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
Haemonetics Stock Summary
Haemonetics competes with Merit Medical, AngioDynamics, AptarGroup, Envista Holdings, and Hologic. Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. It employs 2821 people.
Comparative valuation techniques use various fundamental indicators to help in determining Haemonetics's current stock value. Our valuation model uses many indicators to compare Haemonetics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Haemonetics competition to find correlations between indicators driving Haemonetics's intrinsic value. More Info.
Haemonetics is rated # 4 in return on equity category among its peers. It also is rated # 4 in return on asset category among its peers reporting about 0.45 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Haemonetics is roughly 2.22 . At present, Haemonetics' Return On Equity is projected to increase slightly based on the last few years of reporting. Comparative valuation analysis is a catch-all technique that is used if you cannot value Haemonetics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.
Haemonetics Systematic Risk
Haemonetics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Haemonetics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Haemonetics correlated with the market. If Beta is less than 0 Haemonetics generally moves in the opposite direction as compared to the market. If Haemonetics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Haemonetics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Haemonetics is generally in the same direction as the market. If Beta > 1 Haemonetics moves generally in the same direction as, but more than the movement of the benchmark.
Haemonetics Thematic Clasifications
Haemonetics is part of several thematic ideas from Baby Boomer Prospects to Office Supplies. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic Ideas
Today, most investors in Haemonetics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Haemonetics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Haemonetics growth as a starting point in their analysis.
Price Earnings To Growth Ratio
(0.3)
At present, Haemonetics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting.
Haemonetics March 20, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Haemonetics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Haemonetics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Haemonetics based on widely used predictive technical indicators. In general, we focus on analyzing Haemonetics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Haemonetics's daily price indicators and compare them against related drivers.
Complementary Tools for Haemonetics Stock analysis
When running Haemonetics' price analysis, check to measure Haemonetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Haemonetics is operating at the current time. Most of Haemonetics' value examination focuses on studying past and present price action to predict the probability of Haemonetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Haemonetics' price. Additionally, you may evaluate how the addition of Haemonetics to your portfolios can decrease your overall portfolio volatility.